Related Experiment Video
Updated: Jan 20, 2026
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
[Dual antiplatelet therapy for secondary stroke prevention in patients with acute ischemic stroke. CIERTO group
Ariel Izcovich1, Diego Caruso1, Matías Tisi Baña1
1Grupo CIERTO (Club interhospitalario de lectura crítica para recomendar basados en pruebas), Buenos Aires, Argentina.
Insights
Short-term dual antiplatelet therapy in acute ischemic stroke may reduce recurrence risk. However, this approach might slightly increase bleeding complications, making it suitable for minor strokes or transient ischemic attacks.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Pharmacology
Background:
- Antiplatelet therapy is crucial for managing acute ischemic stroke.
- Dual antiplatelet therapy shows promise in reducing stroke recurrence but carries bleeding risks.
Purpose of the Study:
- To evaluate the efficacy and safety of short-term dual antiplatelet therapy in acute ischemic stroke patients.
- To assess the impact of dual versus single antiplatelet therapy on stroke recurrence and bleeding complications.
Main Methods:
- Rapid systematic review of randomized controlled trials.
- Included studies compared dual antiplatelet therapy with single antiplatelet therapy in acute ischemic stroke patients.
Main Results:
- Dual antiplatelet therapy significantly reduces the risk of stroke recurrence.
- A marginal increase in major bleeding complications was observed with dual antiplatelet therapy.
Conclusions:
- Short-term dual antiplatelet therapy is beneficial for initial management in patients with minor acute ischemic stroke or transient ischemic attack (TIA).
- The reduction in short-term recurrence risk outweighs the potential increase in bleeding complications for this patient subgroup.
Abstract:
One of the main pillars of acute ischemic stroke management is antiplatelet therapy. Different treatment schemes have been compared, suggesting that the combination of multiple antiplatelet drugs is associated with a reduced risk of stroke recurrence. However, it has also been associated with an increased risk of bleeding complications which, in the long term, surpass the mentioned benefits. However, considering that most stroke recurrences occur i n the short term, a time limited double antiplatelet scheme could result in significant benefits to patients with acute ischemic stroke. On this basis, we conducted a rapid systematic review of the literature in order to evaluate the effects of a short-term double antiplatelet therapy both on stroke recurrence and complications. All trials comparing double versus single antiplatelet therapy in patients with acute ischemic stroke were included. Results showed that double therapy reduces recurrence risk but probably marginally increases major bleeding complications. We suggest double antiplatelet therapy for the initial management of patients with minor (Score NIH < or equal to 3 or transient isquemic attack -TIA) acute ischemic stroke.
Related Concept Videos
09:21Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
05:23Motor Dual-Tasks for Gait Analysis and Evaluation in Post-Stroke Patients
07:42Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:34Induction of Acute Ischemic Stroke in Mice Using the Distal Middle Artery Occlusion Technique
02:44Endovascular Treatment of Acute Ischemic Stroke Using the Stent Retriever-Assisted Vacuum-Locked Extraction Technique
09:11Embolic Middle Cerebral Artery Occlusion (MCAO) for Ischemic Stroke with Homologous Blood Clots in Rats